The Top 5 Biosimilar Articles for the Week of August 17

Here are the top 5 biosimilar articles for the week of August 17, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 17, 2020.

Number 5: Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD, practice president and chair of the National Policy Executive Committee for The US Oncology Network.

Number 4: Much has been made of treatments for advanced coronavirus disease 2019 (COVID-19) infection, but early-stage treatments such as monoclonal antibodies (mAbs) and direct-acting antivirals (DAAs) are showing promise, said [Dr] Anthony S. Fauci, MD, director of the National Institute of Allergy and Infection Diseases, in a recent town hall meeting.

Number 3: Biosimilars for the top 10 biologics by revenue have yet to achieve more than a toehold in the United States, which represents a huge missed opportunity for employers, according to Juliana Reed, MS, a vice president and Global Corporate Affairs lead for Pfizer.

Number 2: Employers asserting their own desire to see biosimilars implemented among their employees was the theme of a Pacific Coast day of discussions involving representatives from Walt Disney, Costco, and the California Public Employees’ Retirement System (CalPERS).

Number 1: Celltrion Healthcare finds fault with a critique of equivalence margins used to approve its infliximab biosimilar CT-P13 (Remsima, Inflectra).

To read all of these articles and more, visit centerforbiosimilars.com.